Methyl carnosate, a carnosic acid derivative, attenuates osteoclastogenesis via modulation of RANKL-induced NF-κB activity
Lifang Zhang, Chengxu Xie, Xinyi Bao, Mojtaba Tabandeh, Vishwa Deepak · 2026
Read Methyl carnosate, a carnosic acid derivative, attenuates osteoclastogenesis via modulation of RANKL-induced NF-κB activity by Lifang Zhang, Chengxu Xie, Xinyi Bao, Mojtaba Tabandeh, Vishwa Deepak (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272475.txt.
Description
Lifang Zhang and coauthors test in 2026 a rosemary compound, methyl carnosate, against the bone-eating cells whose excess drives osteoporosis and joint disease. A signal molecule called RANKL switches these cells on through a pathway known as NF-κB. Blocking that pathway is a proven way to protect bone, and plant compounds offer fresh leads.
In cell tests, the compound stopped new bone-eating cells from forming at low doses and beat its parent compound, carnosic acid. Reporter tests showed it dulled NF-κB activity after RANKL treatment, and the master gene for these cells fell as well. The authors put the compound forward as a lead for bone-saving drugs.
Catalog record
| CREATOR | Lifang Zhang, Chengxu Xie, Xinyi Bao, Mojtaba Tabandeh, Vishwa Deepak |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |